ライフサイエンスコーパス: interleukin-6 receptor

1 6 exerts many of its effects via the soluble interleukin-6 receptor.

2 embles cytokine receptors, which include the interleukin-6 receptor.

3 either express low or no detectable surface interleukin-6 receptor.

4 iation with ErbB-2, the EGF-receptor, or the interleukin-6 receptor.

5 GF-alpha, cell adhesion receptor L-selectin, interleukin 6 receptor alpha subunit, beta-amyloid precu

6 ult from a transcriptional downregulation of interleukin-6 receptor alpha (IL-6Ralpha) with IL-6Rbeta

7 te that the proportion of CD5(+) relative to interleukin-6 receptor alpha (IL-6Ralpha)-expressing B c

8 The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on th

9 The efficacy and safety of tocilizumab, an interleukin 6 receptor-alpha inhibitor, was assessed in

10 cient T cells showed decreased expression of interleukin-6 receptor-alpha and other Tfh cell-related

11 sGAP, AP-2, p53BP-2 (p53-binding protein-2), interleukin-6 receptor-alpha, chloride channel CLCN5, an

12 duction of interleukin-6), and serum soluble interleukin-6 receptor (an enhancer of myeloma cell resp

13 ssociated with decreased tissue abundance of interleukin-6 receptors and STAT3.

14 7), adaptive immune response (interleukin32, interleukin 6 receptor), and reactive oxygen species (ne

15 Anakinra, monoclonal antibody to interleukin-6 receptor, and thalidomide each have led to

16 atory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose o

17 on and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.

18 iovascular dysfunction were treated with the interleukin-6 receptor antibody tocilizumab.

19 Interleukin-6 receptor blockade with tocilizumab remains

20 Interleukin 6 receptor-blocking therapy can be effective

21 cacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody toci

22 sly identified gene-protein associations for interleukin-6 receptor, chemokine CC-4, angiotensin-conv

23 cluding T cell factor-1, Ikaros, AP-1, CK-2, interleukin-6 receptor E (IL-6RE), ISRE, GAS, NF-kappaB,

24 Functional variants in the interleukin-6 receptor gene (IL6R) are associated with a

25 Signaling by the interleukin 6 receptor (IL-6R) also activates STAT3 thro

26 s was paralleled by a down-regulation of the interleukin 6 receptor (IL-6R) on naive CD4(+) T cells o

27 ver diseases, by targeting components of the interleukin-6 receptor (IL-6R) complex.

28 es of CD341 cells, simultaneous reduction of interleukin-6 receptor (IL-6R) expression on myeloid pro

29 es to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with di

30 The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated

31 lin-like growth factor receptor (IGF-1R) and interleukin-6 receptor (IL-6R) signaling (eg, IKK/NF-kap

32 /or the clinical monoclonal antibody against interleukin-6 receptor (IL-6R), tocilizumab, prevented M

33 itors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized tha

34 though neither Toll-like receptor (TLR)2 nor interleukin 6 receptor (IL6R) signaling is involved, a r

35 pecifically cleaved by RHBDL2, including the interleukin-6 receptor (IL6R), cell surface protease inh

36 s in the levels of interleukin-6 and soluble interleukin-6 receptor in acute meningococcal septicemia

37 s in the levels of interleukin-6 and soluble interleukin-6 receptor in acute meningococcemia may affe

38 ly that alterations in the levels of soluble interleukin-6 receptor in septic shock could affect the

39 ia is associated with a reduction in soluble interleukin-6 receptor levels in proportion to disease s

40 were analyzed for interleukin-6 and soluble interleukin-6 receptor levels.

41 ls are elevated in patients with MM; soluble interleukin-6 receptor may amplify circulating interleuk

42 petuation has led to the use of an antihuman interleukin-6 receptor monoclonal antibody, tocilizumab.

43 ved by treatment with antibiotics or an anti-interleukin-6 receptor-neutralizing antibody.

44 alpha, tumor necrosis factor-alpha receptor, interleukin-6 receptor, or L-selectin.

45 protein gene, the apolipoprotein E gene, the interleukin-6 receptor protein gene, or the CRP gene its

46 Soluble interleukin-6 receptor returns to levels seen in normal

47 rotein S[rs6123] in the schizophrenia group; Interleukin-6 receptor[rs7553796] in both the control an

48 Soluble interleukin-6 receptor serum levels are elevated in pati

49 s shows that caveolin-1 is co-localized with interleukin-6 receptor signal transducing chain gp130 an

50 ocyte receptor (GLM-R), with homology to the interleukin-6 receptor signal transducing chain, gp130,

51 on to baseline levels through suppression of interleukin-6 receptor signaling.

52 The soluble interleukin 6 receptor (sIL-6R) circulates at elevated l

53 tivation-regulated chemokine (TARC), soluble interleukin 6 receptor (sIL-6R), and soluble tumor necro

54 Generation of the soluble interleukin-6 receptor (sIL-6R) is a prerequisite for pa

55 ow PC labeling indices, higher serum soluble interleukin-6 receptor (sIL-6R) levels, and a higher pro

56 -1 receptor antagonist (IL-1Ra), and soluble interleukin-6 receptor (sIL-6R).

57 active protein [CRP], interleukin 6, soluble interleukin 6 receptor [sIL-6R], soluble gp130, tumor ne

58 thway, including janus kinase-1, gp 130, the interleukin-6 receptor, STAT1, and STAT3, were examined

59 -6 activation of janus kinase-1, gp 130, the interleukin-6 receptor, STAT1, and STAT3.

60 r's laboratory reveals that the gp130-linked interleukin-6 receptor, which usually activates STAT3 pr